

Page 1 of 2 Pages [X] Original [] Substitute [] Supplemental Atty. Docket: KOPCHICK 6.1A

COMBINED DECLARATION (37 CFR 1.63)AND POWER OF ATTORNEY FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

TITLE OF THE INVE	NTION	DIAGNOSIS OF HYPERINSULINEMIA AGAINST SAME	AND TYPE II DIABETES AND PROTECTION				
This declaration is directed to: [] the attached application; [] the application filed in the United States under 35 U.S.C. §111 on, as							
	U.S. Appln. No*; or						
[X] the application which was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/US2004/010191; filed April 2, 2004, entry requested on October 7, 2005*; national stage application received U.S. Appln. No. 10/552,443*; §371/§102(e) date* (* if known)							
[] as amended on (if applicable).							
An Application Data Sheet was filed in reference to this application on October 7, 2005.							
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;							
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;							
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.							
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.							
As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:							
All of the practitioners associated with Customer Number 001444							
Direct all corresponder	nce to the a	ddress associated with Customer Number 0	01444, which is presently:				
BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197							
The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from EDIS as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.							
FULL NAME OF IN	VENTOR	(S)					
Inventor one: John J.			Date: 2-06-06				
Signature: Jelm	JK	re	Citizen of: United States				
V			aut addin				
Inventor two: Bruce k	KELDER .		Date: 2/6/06				
Signature: Bru	ule!	da -	Citizen of: United States				



Page 2 of 2 Pages

Atty. Docket: KOPCHICK6.1A
Title: DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION AGAINST SAME
U.S. Application filed ________, Serial No. 10/552,443
PCT Application filed April 12, 2004 , Serial No. PCT/US2004/010191

Inventor three: Keith S. BOYCE	Date:
Signature:	Citizen of: United States
Inventor four: Andres KRIETE	Date:
Signature:	Citizen of: United States
Inventor five:	Date:
Signature:	Citizen of:
[] Additional inventors or a legal representative are being named on	
All inventors must review application and declaration before signing. All alterprior to execution. No alterations can be made after the declaration is signed inventors.	rations must be initialed and dated by all inventors 1. All pages of the declaration must be seen by all
Resolving conflicts between Application Data Sheets and Declaration occu information governs, (2) if an Application Data Sheet and a declaration are filed except with respect to the naming of inventors and the identification of their cit	the same day, the Application Data Sheet governs,
	•

Page 1 of 2 Pages [X] Original [] Substitute [] Supplemental Atty. Docket: KOPCH	HCK	ICI	IC.	C.	IJ	K	K	١	١	١,	١	١	١	١	J	J	١		ď	
--	-----	-----	-----	----	----	---	---	---	---	----	---	---	---	---	---	---	---	--	---	--

COMBINED DECLARATION (37 CFR 1.63)AND POWER OF ATTORNEY FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

TITLE OF THE INVEN		HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION					
	AGAINST SAME						
This declaration is direct	eted to:						
[] th	e attached application;						
[] th	ie application filed in the Unite	d States under 35 U.S.C. §111 on, as *; or					
[X] th st	[X] the application which was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/US2004/010191; filed April 2, 2004, entry requested on October 7, 2005*; national stage application received U.S. Appln. No. 10/552,443*; §371/§102(e) date						
_		* (* if known)					
[] as amended on _	(if applie	rable).					
An Application Data Sheet was filed in reference to this application on October 7, 2005.							
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;							
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;							
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.							
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.							
As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:							
All of the practitioners associated with Customer Number 001444							
Direct all corresponden	ce to the address associated wi	th Customer Number 001444, which is presently:					
BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197							
The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from EDIS as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.							
FULL NAME OF IN	VENTOR(S)	•					
Inventor one: <u>John J. J.</u>	KOPCHICK	Date:					
Signature:		Citizen of: <u>United States</u>					
Inventor two: Bruce K	ELDER	Date:					
Signature:		Citizen of: United States					

Page 2 of 2 Pages

Atty. Docket: KOPCHICK6.1A

Title: <u>DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION AGAINST SAME</u>

U.S. Application filed ________, Serial No. <u>10/552,443</u>

PCT Application filed <u>April 12, 2004</u> , Serial No. <u>PCT/US2004/010191</u>

Inventor three: Keith S. BOYCE Signature: Least Supplementary	Date: Time 28, 200C Citizen of: United States
Inventor four: Andres KRIETE Signature:	Date: Citizen of: <u>United States</u>
Inventor five: Signature: [] Additional inventors or a legal representative are being named on	Date: Citizen of: additional form(s) attached hereto.
All inventors must review application and declaration before signing. All alt prior to execution. No alterations can be made after the declaration is signe inventors. Resolving conflicts between Application Data Sheets and Declaration occi information governs, (2) if an Application Data Sheet and a declaration are file except with respect to the naming of inventors and the identification of their circumstance.	d. All pages of the declaration must be seen by all urs as follows: (1) normally, the latest submitted at the same day, the Application Data Sheet governs,

Page 1 of 2 Pages [X] Original [] Substitute [] Supplemental Atty. Docket: KOPCHICI	Page 1 of 2 Pages	[X] Original	Substitute [] Supplemental	Atty. Docket: KOPCHICK6
---	-------------------	--------------	--------------	----------------	-------------------------

COMBINED DECLARATION (37 CFR 1.63)AND POWER OF ATTORNEY FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

TITLE OF THE INVENTION	DIAGNOSIS OF HYPERINSULINEMIA AGAINST SAME	AND TYPE II DIABETES AND PROTECTION					
							
This declaration is directed to: [] the attached	l application;						
[] the applicat	tion filed in the United States under 35 U.S.C.	§111 on, as					
U.S. Appln.	. No*; or	log 25 ILS C \$271 by ontry into the ILS notional					
stage of an	international (PCT) application, <u>PCT/US200</u> 2005*; national stage application received U.S	ler 35 U.S.C. §371 by entry into the U.S. national 04/010191; filed April 2, 2004, entry requested on S. Appln. No. 10/552,443*; §371/§102(e) date* (* if known)					
[] as amended on	(if applicable).						
An Application Data Sheet was filed in reference to this application on October 7, 2005.							
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;							
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;							
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.							
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.							
As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:							
All of the practitioners associated with Customer Number 001444							
Direct all correspondence to the a	address associated with Customer Number 00	01444, which is presently:					
BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197							
The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from EDIS as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.							
FULL NAME OF INVENTOR	2(S)						
Inventor one: John J. KOPCHIC	CK	Date:					
Signature:		Citizen of: United States					
Inventor two: Bruce KELDER		Date:					
Signature:		Citizen of: United States					

Atty. Docket: KOPCHICK6.1A Page 2 of 2 Pages Title: DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION AGAINST SAME , Serial No. 10/552,443 U.S. Application filed , Serial No. PCT/US2004/010191 PCT Application filed April 12, 2004 Date: Inventor three: Keith S. BOYCE Signature: Inventor four: Andres KRIETE Citizen of: United States Inventor five: _ Citizen of: Signature: additional form(s) attached hereto. [] Additional inventors or a legal representative are being named on _ All inventors must review application and declaration before signing. All alterations must be initialed and dated by all inventors prior to execution. No alterations can be made after the declaration is signed. All pages of the declaration must be seen by all inventors. Resolving conflicts between Application Data Sheets and Declaration occurs as follows: (1) normally, the latest submitted information governs, (2) if an Application Data Sheet and a declaration are filed the same day, the Application Data Sheet governs, except with respect to the naming of inventors and the identification of their citizenship. See 37 CFR 1.76(d).